David M. Charytan, MD, MSc
Director of the Division of Nephrology and the Norman S. Wikler Professor of Medicine at New York University Langone Medical Center
This lectureship was established to honor Dr. J. Michael Lazarus for his major contributions to the clinical science and care of dialysis patients, and to recognize individuals whose research has yielded novel insights related to renal replacement therapy.
Dr. David M. Charytan is the Director of the Division of Nephrology and the Norman S Wikler Professor of Medicine at New York University Langone Medical Center. In addition to maintaining a broad clinical practice in general nephrology, Dr. Charytan is an active researcher with a focus on chronic dialysis, diabetic kidney disease and cardiovascular disease in the setting of chronic kidney disease. Using large databases, translational and cohort studies, and clinical trials to explore his research interests, Dr. Charytan has published more than 200 manuscripts and has served as the principal investigator on multiple grants with continuous funding by foundations and NIH since 2006.
Dr. Charytan has served as a founding Steering Committee member of the NIH Hemodialysis Novel Therapies Consortium where he served as the lead PI of two of the network’s trials. He has helped lead multiple trials as member of the executive leadership team including the HOPE trial (pain in hemodialysis dependent end stage kidney disease), the CREDENCE trial (diabetic nephropathy), the Monitoring in Dialysis Trial (arrhythmia monitoring in hemodialysis patients) and the WEDHEAD trial (wearable defibrillator in hemodialysis patients). In addition, Dr. Charytan is an associate editor at the Clinical Journal of the American Society of Nephrology and previously was a member of the American Society of Nephrology’s Dialysis Advisory Group.
View full press release here.
![](https://www.kidney.org/sites/default/files/styles/large/public/480x480_david_charytan_-_photo.jpg?itok=JFVKy7sf)
Dr. Charytan is an active researcher with a focus on chronic dialysis, diabetic kidney disease and cardiovascular disease in the setting of chronic kidney disease.